HOUSTON--(BUSINESS WIRE)--CytoGenix, Inc. (CYGX), today announced that the National Institute of Allergy and Infectious Diseases of NIH has awarded a Phase I Small Business Innovation Research Grant (SBIR) to CytoGenix, Inc. Dr. Frederic Kendirgi will be the principal investigator. The grant entitled, “Novel DNA Manufacturing Process: Cell-Free Production and Testing of a New Multivalent DNA Vaccine Against Human Influenza (H5N1)” received an award of approximately $136,000.
